An attempt to educate students about the risk factors that may eventually result in diseases. It is now unacceptable to wait until preventable diseases occur and then offer remedies. Future physicians will not only diagnose and treat diseases such as coronary artery, bypass graft, or percutaneous transluminal coronary angioplasty, but they will help patients prevent the abnormalities responsible for the diseases. Recognizing risk factors leads to specific therapy for high risk patients with hypertension, abnormal lipids, obesity, diabetes, emphysema, etc. Certain diseases cluster, thus sharing a common pathogenetic mechanism, or common underlying risk factor. The insulin resistance syndrome is characterized by diabetes, obesity, hypertension, dyslipidemia (high cholesterol), atherosclerosis (clogging of medium and large arteries by plaque-like deposits), and hyperandrogenism (excessive secretion of masculating substances). Emphasis will be placed on these factors, some of the most prevalent in western societies. Volunteer students will be admitted to the GCRC for one night during the first semester of medical school. After admission, students will be interviewed by a nutritionist to obtain a typical 24 hour intake, food frequency, and preliminary information as to life style behaviors. Skinfold measurement to determine body fat, Body Mass Index, and Waist Hip Ratio will be taken during the interview. A life style questionnaire will be filled out by the student. After an evening meal, the student will fast until 8:00a.m. the next day. The student will collect a timed urine for nitrogen analysis. Before arising and while supine, the student will undergo indirect calorimetry to determine resting energy expenditure and substrate oxidation. This is achieved by placing a plastic, ventilated canopy over the head for approximately 20 minutes while oxygen consumption and carbondioxide production are measured. Blood samples of no more than 30cc. will be obtained for the measurement of glucose, insulin, dehydroepiandrosterone (DHEA), fasting lipid profile, and blood chemistries. Bioelectrical impedence will also be performed. The student will then receive breakfast.

Project Start
1999-12-01
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
38
Fiscal Year
2000
Total Cost
$648
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8
Poklepovic, Andrew; Youssefian, Leena E; Youseffian, Leena et al. (2013) Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs 31:937-42
Holkova, Beata; Supko, Jeffrey G; Ames, Matthew M et al. (2013) A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 19:1873-83
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93

Showing the most recent 10 out of 367 publications